Contribution: Industrial Research Assistance Program – Contributions to Firms
Notch Therapeutics (Canada) Inc
$470,000.00
Defining Notch Therapeutics’ manufacturing process.
EF 2023-24 · 2023-07-01
Résumé
Notch Therapeutics aims to develop a manufacturing process for producing cellular therapy products for cancer treatment that is reliable and cost-effective to allow mainstream access to these new powerful medicines. This project supports cell manufacturing scale-up to enable rapid testing of potential products in cancer model systems.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Toronto|Toronto, Ontario, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
719140089
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2024-06-30
Agreement Number
1008560
Agreement Start Date
2023-07-01
Agreement Title
Defining Notch Therapeutics’ manufacturing process.
Agreement Title (French)
Définition du processus de fabrication de Notch Therapeutics.
Agreement Type
Contribution
Agreement Value
$470,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Notch Therapeutics aims to develop a manufacturing process for producing cellular therapy products for cancer treatment that is reliable and cost-effective to allow mainstream access to these new powerful medicines. This project supports cell manufacturing scale-up to enable rapid testing of potential products in cancer model systems.
Description (French)
Notch Therapeutics vise à mettre au point un processus de fabrication de produits de thérapie cellulaire pour le traitement du cancer qui soit fiable et rentable afin de permettre un accès général à ces nouveaux médicaments puissants. Ce projet soutient la mise à l’échelle de la fabrication de cellules pour permettre de tester rapidement des produits potentiels dans des systèmes de modèles de cancer.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
University--Rosedale
Federal Riding (French)
University--Rosedale
Federal Riding Number
35110
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
719140089
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Notch Therapeutics (Canada) Inc
Recipient Operating Name
Notch Therapeutics (Canada) Inc
Recipient Postal Code
M5G 1L7
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2023-2024-Q2-1008560
